On April 26, Discern Health partnered with the National Pharmaceutical Council (NPC) to host a webinar discussing the findings of the recently published “Improving Oncology Quality Measurement in Accountable Care” white paper.
The webinar, which was moderated by NPC Vice President of Health Services Research Kimberly Westrich and featured Discern Health Partner Tom Valuck, discussed identified measure gaps for 10 high-priority cancers and potential avenues to improve measurement. Three experts in quality measurement and oncology reacted to the findings:
- Mark McClellan, MD, PhD, director of the Duke-Margolis Center for Health Policy
- Robert S. Miller, MD, FACP, FASCO, vice president and medical director, CancerLinQ at the American Society of Clinical Oncology (ASCO)
- Alan Balch, PhD, chief executive officer at the National Patient Advocate Foundation.